In an attempt to bolster its presence in neurology, Sanofi has agreed to acquire Vigil Neuroscience for a total equity value of US$470 M. The deal will provide Sanofi access to VG-3927, currently in a Phase I study to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease. However, Sanofi will not be acquiring iluzanebart, another pipeline asset, which will instead revert to Amgen. This transaction adds to the string of M&A deals announced by the French pharma giant in 2025, further reinforcing its expansion strategy.